Where does Proteostasis Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Proteostasis Therapeutics, Inc. ranks #12,635 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Proteostasis Therapeutics, Inc. hold?

Proteostasis Therapeutics, Inc. holds 24 US utility patents granted between 2016 and 2023, spanning 7 technology areas.

What is Proteostasis Therapeutics, Inc.'s Innovation Score?

Proteostasis Therapeutics, Inc. has an Innovation Score of 33.3 out of 100 (44th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Proteostasis Therapeutics, Inc. focus on?

Proteostasis Therapeutics, Inc.'s top technology area is C07D (Heterocyclic Compounds) with 24 patents, ranking #357 of 3,165 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

Is Proteostasis Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Proteostasis Therapeutics, Inc.'s recent grant velocity is +40% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Proteostasis Therapeutics, Inc.'s patents?

Proteostasis Therapeutics, Inc.'s patents average 18.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Proteostasis Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Proteostasis Therapeutics, Inc.

USPTO PatentsView assignee record - 24 granted patents across 7 technology areas, recorded in grant years 2016–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Proteostasis ranks #12,635 of 49,997 tracked US assignees by granted-patent volume, with 24 patents across 7 technology areas.

#12,635
of 49,997 US assignees by volume: 44th percentile
by Innovation Score (33.3/100): 18.2
avg claims per patent: +40%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R12635 · US Corporation #12,635 · 24 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-UP · BOOK-FULL

GRANTS-SMALL 24 grants
MID-PACK #12,635/49,997
PHOTO-FINISH Premier Dental…
CPC-NARROW C07D · 7 areas
INNOV-THIN 33.3/100
CLAIMS-RICH 18.2 claims/avg
TYPE-USCORP US Corporation
VEL-UP +40% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Premier Dental Products Company (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Proteostasis’s 33.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 11.1 pts (33%) Velocity 1.9 pts (6%) Breadth 9.4 pts (28%) Claim depth 10.9 pts (33%)

Qualcomm Incorporated · highest

85
Proteostasis… · this assignee

33
Imation · near

33
Raymx Microelectronics · near

33
THE SUN Lock · near

33
Ukima Chemicals &… · near

33
3D Lighting… · lowest

7

What this shows Proteostasis's Innovation Score is 33.3/100 (44th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Proteostasis?

Each dot is one of Proteostasis’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Proteostasis’s own 18.2 claims/patent is ABOVE the 12.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Proteostasis vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Proteostasis's grants concentrate

Proteostasis Therapeutics, Inc. is a focused PatentsView assignee: 7 CPC subclasses with 100% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2020 (6 grants) versus a trough of 1 in 2016. By volume, Proteostasis sits between Premier Dental Products Company and Renk GmbH.

Proteostasis's three-year grant acceleration

Proteostasis Therapeutics, Inc. shows 4 grants in 2022–2024 against only 14 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Premier Dental Pr…

24
Pricewaterhouseco…

24
Proqr Therapeutic…

24
Professional Comp…

24
Rachio

24
Rade TecnologÍAS…

24
Raumedic

24
Renk

24
Proteostasis Ther… ◀

24

What this shows Proteostasis holds 24 patents at rank #12,636, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Proteostasis

By rank, the assignees closest to #12,636 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Proteostasis's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Proteostasis, neither rank-band nor same-CPC leaders (those blocks stay above). In C07D (Heterocyclic Compounds), Proteostasis ranks #357 of 3,165 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (33 here).

Imation Corp. 33 Raymx Microelectronics, Corp. 33 THE SUN Lock Company Limited 33 Ukima Chemicals & Color MFG. Co., Ltd. 33

Proteostasis's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

33 44th percentile higher than 44% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Proteostasis Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	1	4.2%
2017	4	16.7%
2018	1	4.2%
2019	4	16.7%
2020	6	25.0%
2021	4	16.7%
2022	2	8.3%
2023	2	8.3%

Which technologies does Proteostasis Therapeutics, Inc. patent most?

C07D - Heterocyclic Compounds 24

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 18

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 16

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 7

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 4

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 2

C07C - Acyclic OR Carbocyclic Compounds 2

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Proteostasis Therapeutics, Inc.'s patent record in context - here's where to go next.

Proteostasis Therapeutics, Inc.'s lead technology class is C07D (Heterocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #12,635 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Proteostasis Therapeutics, Inc. against Premier Dental Products Company, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 33.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.